Literature DB >> 9467539

The dexamethasone-suppressed corticotropin-releasing hormone stimulation test differentiates mild Cushing's disease from normal physiology.

J A Yanovski1, G B Cutler, G P Chrousos, L K Nieman.   

Abstract

The dexamethasone-suppressed CRH test (Dex-CRH test) differentiates patients with Cushing's syndrome (CS) from those with pseudo-Cushing states, who have decreased ACTH responses to CRH because of negative feedback exerted by chronic hypercortisolism. Normal subjects, however, have not been studied with the Dex-CRH test, raising concern that this test might not separate patients with CS from patients with normal adrenal function. To determine whether the criterion that separates CS from pseudo-Cushing states also would differentiate patients with Cushing's disease (CD) from individuals with eucortisolism, we studied 20 healthy volunteers during low-dose (2 mg/day) dexamethasone suppression, and then during the Dex-CRH test (CRH stimulation test performed 2 h after completion of low-dose dexamethasone suppression), and contrasted their results with those of 20 patients with surgically proven mild CD [urine free cortisol (UFC) < 1000 nmol/day). Basal UFC was significantly greater in patients with CD (P < 0.001) but within the normal range (55-250 nmol/day) in 4 patients. During low-dose dexamethasone suppression, a UFC less than 100 nmol/day (36 micrograms/day) was found in all but 1 volunteer subject, and a urine 17-hydroxycorticosteroid excretion less than 14.6 mumol/day (5.3 mg/day) was found in all but 2 subjects. During the Dex-CRH test, plasma cortisol less than 38 nmol/L was found in all 20 normal volunteers until 30 min after CRH administration. By contrast, the 15-min CRH-stimulated plasma cortisol exceeded 38 nmol/L in all patients with CD (P < 0.001). Plasma dexamethasone measured just before CRH administration was similar in normal volunteers (13.0 +/- 6.1 mumol/L) and patients with CD (16.4 +/- 6.4 mumol/L). We conclude that cortisol measurements obtained during the Dex-CRH test are suppressed in normal volunteers below those found in mild CD. These results suggest that the Dex-CRH test may be useful in the evaluation of CS in patients without significant hypercortisoluria. However, its value in patients with episodic hormonogenesis has not been tested.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467539      PMCID: PMC7257118          DOI: 10.1210/jcem.83.2.4568

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Cyclical Cushing's syndrome.

Authors:  P M Stewart; P Venn; D A Heath; G Holder
Journal:  Br J Hosp Med       Date:  1992 Jul 29-Sep 1

Review 2.  Cushing's syndrome: a review of diagnostic tests.

Authors:  L Crapo
Journal:  Metabolism       Date:  1979-09       Impact factor: 8.694

3.  "Normal suppression" to dexamethasone in Cushing's disease: an expression of decreased metabolic clearance for dexamethasone.

Authors:  J F Caro; A W Meikle; J H Check; S N Cohen
Journal:  J Clin Endocrinol Metab       Date:  1978-09       Impact factor: 5.958

4.  The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome.

Authors:  L K Nieman; G P Chrousos; E H Oldfield; P C Avgerinos; G B Cutler; D L Loriaux
Journal:  Ann Intern Med       Date:  1986-12       Impact factor: 25.391

5.  The use of relative operating characteristic (ROC) curves in test performance evaluation.

Authors:  J R Beck; E K Shultz
Journal:  Arch Pathol Lab Med       Date:  1986-01       Impact factor: 5.534

6.  Cushing's syndrome: a prospective study of diagnostic methods.

Authors:  R L Eddy; A L Jones; P F Gilliland; J D Ibarra; J Q Thompson; J F MacMurry
Journal:  Am J Med       Date:  1973-11       Impact factor: 4.965

7.  Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications.

Authors:  P W Gold; D L Loriaux; A Roy; M A Kling; J R Calabrese; C H Kellner; L K Nieman; R M Post; D Pickar; W Gallucci
Journal:  N Engl J Med       Date:  1986-05-22       Impact factor: 91.245

8.  Comparison between the suppressive effects of dexamethasone and loperamide on cortisol and ACTH secretion in some pathological conditions.

Authors:  G P Bernini; G F Argenio; F Cerri; F Franchi
Journal:  J Endocrinol Invest       Date:  1994-11       Impact factor: 4.256

9.  Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states.

Authors:  J A Yanovski; G B Cutler; G P Chrousos; L K Nieman
Journal:  JAMA       Date:  1993-05-05       Impact factor: 56.272

10.  CRF in the differential diagnosis of Cushing's syndrome: a comparison with the dexamethasone suppression test.

Authors:  A B Grossman; T A Howlett; L Perry; D H Coy; M O Savage; P Lavender; L H Rees; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1988-08       Impact factor: 3.478

View more
  16 in total

1.  Circadian variation in Cushing's disease and pseudo-Cushing states by analysis of F and ACTH pulsatility.

Authors:  J M Cunningham; O M Buxton; R E Weiss
Journal:  J Endocrinol Invest       Date:  2002-10       Impact factor: 4.256

2.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

Review 3.  The glucocorticoid receptor and its expression in the anterior pituitary and the adrenal cortex: a source of variation in hypothalamic-pituitary-adrenal axis function; implications for pituitary and adrenal tumors.

Authors:  George Briassoulis; Svetozar Damjanovic; Paraskevi Xekouki; Hervé Lefebvre; Constantine A Stratakis
Journal:  Endocr Pract       Date:  2011 Nov-Dec       Impact factor: 3.443

Review 4.  Polycystic ovarian syndrome: diagnosis and management.

Authors:  Michael T Sheehan
Journal:  Clin Med Res       Date:  2004-02

Review 5.  Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia.

Authors:  Hershel Raff; Susmeeta T Sharma; Lynnette K Nieman
Journal:  Compr Physiol       Date:  2014-04       Impact factor: 9.090

Review 6.  Cushing's syndrome: from physiological principles to diagnosis and clinical care.

Authors:  Hershel Raff; Ty Carroll
Journal:  J Physiol       Date:  2015-01-05       Impact factor: 5.182

7.  Specificity of screening tests for Cushing's syndrome in an overweight and obese population.

Authors:  Smita K Baid; Domenica Rubino; Ninet Sinaii; Sheila Ramsey; Arthur Frank; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2009-07-14       Impact factor: 5.958

8.  The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits.

Authors:  Estelle Louiset; Constantine A Stratakis; Véronique Perraudin; Kurt J Griffin; Rossella Libé; Sylvie Cabrol; Bruno Fève; Jacques Young; Lionel Groussin; Jérôme Bertherat; Hervé Lefebvre
Journal:  J Clin Endocrinol Metab       Date:  2009-04-21       Impact factor: 5.958

Review 9.  Evaluation of the hypothalamic-pituitary-adrenal axis function in childhood and adolescence.

Authors:  George P Chrousos; Tomoshige Kino; Evangelia Charmandari
Journal:  Neuroimmunomodulation       Date:  2009-06-29       Impact factor: 2.492

10.  Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing's syndrome.

Authors:  Elena Valassi; Brooke Swearingen; Hang Lee; Lisa B Nachtigall; Daniel A Donoho; Anne Klibanski; Beverly M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2009-10-22       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.